BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 16551732)

  • 1. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization.
    Foong SC; Abbott DH; Zschunke MA; Lesnick TG; Phy JL; Dumesic DA
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2327-33. PubMed ID: 16551732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased adiposity enhances intrafollicular estradiol levels in normoandrogenic ovulatory women receiving gonadotropin-releasing hormone analog/recombinant human follicle-stimulating hormone therapy for in vitro fertilization.
    Dumesic DA; Lesnick TG; Abbott DH
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1438-41. PubMed ID: 17244784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
    Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
    Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.
    Dumesic DA; Lesnick TG; Stassart JP; Ball GD; Wong A; Abbott DH
    Fertil Steril; 2009 Jul; 92(1):217-21. PubMed ID: 18675414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization.
    Desforges-Bullet V; Gallo C; Lefebvre C; Pigny P; Dewailly D; Catteau-Jonard S
    Fertil Steril; 2010 Jun; 94(1):198-204. PubMed ID: 19361798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
    Pierre A; Peigné M; Grynberg M; Arouche N; Taieb J; Hesters L; Gonzalès J; Picard JY; Dewailly D; Fanchin R; Catteau-Jonard S; di Clemente N
    Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis.
    Welt CK; Taylor AE; Fox J; Messerlian GM; Adams JM; Schneyer AL
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5582-7. PubMed ID: 16030174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome.
    Segal S; Glatstein I; McShane P; Hotamisligil S; Ezcurra D; Carson R
    Fertil Steril; 2009 May; 91(5):1755-9. PubMed ID: 18394616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome?
    La Marca A; Pati M; Giulini S; Levratti P; Caretto S; Volpe A
    Gynecol Endocrinol; 2005 Nov; 21(5):292-4. PubMed ID: 16373249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of follicular vascularization in normal versus polycystic ovaries during in vitro fertilization as measured using 3-dimensional power Doppler ultrasonography.
    Järvelä IY; Sladkevicius P; Kelly S; Ojha K; Campbell S; Nargund G
    Fertil Steril; 2004 Nov; 82(5):1358-63. PubMed ID: 15533360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.